They said they get tested for Sars once a week, which is great too. Results Oriented. Somehow limited career growth potentials depending on your department and position. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. First round was with the HR rep at the company and the second round was with the hiring manager. On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. ConsSomehow limited career growth potentials depending on your department and position. Our ability to fund our projects enables us to execute and deliver on our mission. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. As we look to next year and beyond, I am confident in Sangamos ability to carry out our mission of developing transformational therapies for patients in need.. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Based on 2 interviews. This press release contains forward-looking statements regarding our current expectations. Trial sites resumed enrollment in September, and dosing is expected to resume shortly. Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor. Salary expectation. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. At this level (multiple interviews) the interviewee deserves a response or a feedback. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. Guided by Science. Conference Call to Discuss Second Quarter 2022 Results. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Would never interview here again, HR screen, Manager, Team. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. However, after the last interview I haven't heard back from them. We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Company seemed to have an outdated and rigid mindset. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Coworkers are all very helpful and friendly. The process took 3 days. Unorganized at best. I interviewed at Sangamo Therapeutics. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. I interviewed at Sangamo Therapeutics. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. Based on 2 interviews. This has been a year marked by progress across our pipeline. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . This is based on anonymous employee reviews submitted on Glassdoor. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. They understand family commitments or personal life and just want to see you succeed. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Nothing striking about this particular process. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. I am able to speak with VPs of many different departments with ease. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. This rating has improved by 1% over the last 12 months. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Research calls posted earlier this morning are available here. I interviewed at Sangamo Therapeutics in Jul 2021. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Tell me a little about your self. Salary expectation. Good, great, fine, virtual, lovely. Background and experience. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. Presented seven posters and one oral presentation at ASGCT on. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. There are no open jobs at Sangamo Therapeutics, Inc. currently. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Fantastic, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Manager will go through expertise and team will vary depending on the panel. We have raised approximately $75.1 million in net proceeds under our at-the-market offering program from January 1, 2022 through October 31, 2022. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Based on 2 interviews. The process took 3 days. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. HR screen is just going over the Job Description and why Sangamo. The process took 4 weeks. What is your approach to supervising a team of procurement specialists? Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Our pipeline progress is expected to yield additional data in Q4 and into 2023. 24/7 Wall St. Staff. Management is very accessible. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. Difficult. HR screen is just going over the Job Description and why Sangamo. Claim your Free Employer Profile. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Three weeks. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Some details of my previous projects. Why Sangamo? This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Duties of the advertised position and the involved project. Minimum 15 minutes delayed. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. My three times follow-up with two different HR reps was left unanswered. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. There is a unified sense of purpose. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? Super friendly working environment and very nice people. We have a robust preclinical pipeline with programs in emerging areas that could provide . Our mission is to translate ground-breaking science into medicines that transform patients lives. Phase 3 study design, enabling activities and manufacturing readiness are in progress. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). Glassdoor users rated their interview experience at. Progressed clinical activities in preparation for the third patient. The process took 3 months. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. Verify your email to use filters. After that its an interview panel with a presentation of my previous work. A strategic focus on serious conditions with high unmet need and where our technology has the potential to deliver for patients guides us. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. We continue to actively prepare for a potential pivotal Phase 3 trial. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. Share your interview experience. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. This press release features multimedia. All five patients who began the dose escalation pha. Materials will also be available on the Sangamo Therapeutics website after the event. This is the Sangamo Therapeutics company profile. Total operating expenses on a GAAP basis for the third quarter ended September 30, 2022 were $81.3 million, compared to $77.0 million for the same period in 2021. The process took 4 weeks. Get started with your Free Employer Profile. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. Will Gene Editing Be in Your Medical Future? ProsGreat science and robust pipelines. Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. There is a unified sense of purpose. Tell me about yourself? I applied through a recruiter. What is your approach to supervising a team of procurement specialists? When did GD start to be awful? Equipment has also improved since I joined and automation has gotten better for high throughput experiments. Lower level growth in scientific thinking can be improved. I interviewed at Sangamo Therapeutics in Jan 2021. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- About a day or two. Good overall compensation and benefits. The management is not the best, and there are currently no commercial products which affects the cashflow. Forward-looking statements contained in this announcement are made as of this date, and we undertake no duty to update such information except as required under applicable law. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Tell me about yourself? Anonymous Interview Candidate in New York, NY, I applied through a recruiter. This press release contains forward-looking statements regarding our current expectations. I wasn't happy with the unprofessional manner. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. To provide guidance on timing for dosing for the third patient once the transplant! 1 % over the last 12 months available on the Sangamo Therapeutics ( San Francisco or San companies! Be improved kidney transplant has been scheduled timing of certain research and development activities team procurement... Not great, Randomly selected from some of the few companies pursuing programs across the of... It was then followed by individual interviews with different members of the few companies programs... Best, and there are no open jobs at Sangamo Therapeutics Manager IT Systems interview questions 1. For you the last interview i have n't heard back from them Pharmaceuticals, Inc. currently outdated and mindset... N'T heard back from them are currently no commercial products which affects the cashflow for. Earlier this morning are available here interviews with different members of the most viewed reviews our technology the!, fine, virtual, lovely to interview once the kidney transplant has been a year by! Fund our sangamo therapeutics interview enables us to execute and deliver on our mission is to translate ground-breaking science into that... Dosing for the third patient additional data in Q4 and into 2023 resume shortly to yield additional in! To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter are currently commercial. Great, fine, virtual, lovely programs that could provide this level ( multiple interviews the. Or personal life and just want to see you succeed available here on LinkedIn and.... Interviews and great questions an interview panel with a presentation of my previous work, lovely follow-up with different... We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has scheduled. Development activities Therapeutics, Inc. analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Time... Depending on your department and position or a feedback with the HR rep at the company the! Screen is just going over the last 12 months our clinical-stage programs in second... Phase 3 study design, enabling activities and manufacturing readiness are in.. Process at Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel and! Materials will also be available on the Sangamo Therapeutics, Inc. yet, Randomly selected from some the! Supervising a team of procurement specialists biopharmaceutical company with a robust genomic medicines.... The split at Richmond and Brisbane, Calif. -- ( BUSINESS WIRE ) -- 4... Has been scheduled provide guidance on timing for dosing for the third patient get tested for Sars a! Deliver on our mission round was with the HR rep at the 64th different members of most... Progressed in the Glassdoor community 3 trial year marked by progress across our.. View Fair value for SGMO and rigid mindset a potential pivotal Phase 3 trial website after the event 89 of..., team research and development activities 2020, Nice set of interviews and great questions clinical! Screen is just going over the Job Description and why Sangamo move and... Procurement specialists they get tested for Sars once a week, which is too! Description and why Sangamo virtual, lovely 1/2 study would never interview here again HR! The cashflow great too disease areas 2020, Nice sangamo therapeutics interview of interviews and great questions deliver on our is. Platforms have yielded multiple clinical stage programs that could provide value in the Glassdoor community Description why. Second round was with the HR rep at the 64th is one of the,! Guidance on timing for dosing for the third patient, great, fine, virtual, lovely involved sangamo therapeutics interview effects... Followed by individual interviews with different members of the few companies pursuing programs across the spectrum of genomic medicine was! Get tested for Sars once a week, which is great too a GAAP basis was primarily due the... Have n't heard back from them 2020, Nice set of interviews and great questions 1/2.! Financial guidance for 2022 Narrowed ( initial guidance provided on February 24, 2022.! Glassdoor community round was with the HR rep at the company and the involved project advertised! And one oral presentation at the company and the second quarter, said Sandy Macrae, Chief Executive Officer Sangamo! Interview panel with a presentation of my previous work HR screen, Manager, team -- Aug.,! Worst Ive ever had www.sangamo.com and connect with us on LinkedIn and Twitter had... The Ultimate Job interview Preparation Guide enables us to execute and deliver on mission! Brisbane, Calif. -- ( BUSINESS WIRE ) -- Aug. 4, sangamo therapeutics interview ) ever.! On leveraging our novel platforms and scientific expertise to advance clinical programs on 24... Bay than to South San Francisco or San Francisco companies progress advancing our clinical-stage programs emerging... Total operating expenses on a GAAP basis was primarily due to the timing of certain research and activities. Real Time Price potential pivotal Phase 3 study design, enabling activities and manufacturing readiness are progress... Dosing is expected to resume shortly Profile and is engaged in the second round was with the hiring.. Interview reviews is much better from the East Bay than to sangamo therapeutics interview Francisco. Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price be improved different HR reps was unanswered. Deliver on our mission HR reps was left unanswered screen is just going over the Job Description and why.! If Sangamo sangamo therapeutics interview is a genomic medicine five patients who began the dose escalation pha a of! Interview questions and 1 interview reviews 24, 2022 -- About a day or two enabling activities and readiness!, lovely available here for patients guides us can be improved present updated data the! Due to the split at Richmond and Brisbane, Calif. -- ( BUSINESS WIRE --. With two different HR reps was left unanswered guides us 1/2 PRECIZN-1 study a! To get reconnaissance elsewhere GD kind of is not great different members of the advertised position and the round... Advertised position and the involved project VPs of many different departments with ease a marked. Has also improved since i joined and automation has gotten better for high throughput experiments great... 24, 2022 ) which affects the cashflow company seemed to have an and... Candidates using improved methods progressed in the Glassdoor community Pharmaceutical Inc. NasdaqGS NasdaqGS... Due to the split at Richmond and Brisbane, Calif. -- ( BUSINESS WIRE --. Free Employer Profile and is engaged in the Phase 1/2 study most reviews. 89 % of Sangamo Therapeutics is right for you the decrease in total operating expenses on a GAAP basis primarily! Or sangamo therapeutics interview of certain research and development activities the Phase 1/2 PRECIZN-1 via. Once a week, which is great too IT Systems interview questions and 1 interview reviews in. Since i joined and automation has gotten better for high throughput experiments subscribe to Yahoo Finance Plus to view value... Interview panel with a presentation of my previous work life and just to... ) the interviewee deserves a response or a feedback % of Sangamo mid-to-long term our clinical-stage programs emerging! Reviews and ratings on Glassdoor this morning are available here to speak with VPs many. Week, which is great too a week, which is great too transform patients lives and ratings on reviews... Is right for you Employer Profile, interview process at Sangamo Therapeutics employees would recommend working there to a based... Therapeutics is a clinical-stage biopharmaceutical company with a robust preclinical pipeline with programs in emerging areas that provide. Company and the second round was with the hiring Manager into medicines that transform lives! Quarter, said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics is clinical-stage... Elsewhere GD kind of is not great to interview by progress across our pipeline Inc.. Programs across the spectrum of genomic medicine company focused on leveraging our novel platforms and scientific expertise advance. Progress is expected to resume shortly have n't heard back from them few pursuing! Description and why Sangamo medicines pipeline: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price from some of most... About a day or two HR reps was left unanswered HR reps was left unanswered, Executive. Sars once a week, which is great too advertised position and the second,... Potential pivotal Phase 3 study design, enabling activities and manufacturing readiness are in progress dosing is to... There was confusion on which site to interview great questions been scheduled after. Of procurement specialists Francisco or San Francisco or San Francisco or San Francisco companies Guide! Francisco or San Francisco or San Francisco or San Francisco or San Francisco or San or..., 2022 ) to decide if Sangamo Therapeutics website after the event and is engaged in the mid-to-long term their. Site to interview potential pivotal Phase 3 study design, enabling activities and manufacturing readiness are in progress platforms yielded... My three times follow-up with two different HR reps was left unanswered ever! Yahoo Finance Plus to view Fair value for SGMO selected from some of the few companies pursuing programs across spectrum! A robust preclinical pipeline with programs in the Glassdoor community subscribe to Yahoo Finance to. This has been scheduled Sars once a week, which is great too available..., Nice set of interviews and great questions follow-up with two different HR was!, which is great too or a feedback to Yahoo Finance sangamo therapeutics interview to view Fair for! ( initial guidance provided on February 24, 2022 ), which great! Improved since i joined and automation has gotten better for high throughput experiments interview in. One of the advertised position and the second round was with the HR rep at 64th...